Echo IQ Limited has entered a significant reseller agreement with SARC MedIQ, a prominent US-based provider of imaging workflow solutions serving more than 300 healthcare facilities and over 1,500 physicians. Through this arrangement, Echo IQ gains immediate access to an extensive network of US hospitals, cardiology practices, and clinics, with SARC MedIQ’s dedicated sales force set to expedite the adoption of Echo IQ’s AI-driven early aortic stenosis detection platform, EchoSolv AS. Under the terms of the agreement, Echo IQ will initially be compensated on a per scan basis from the network’s member facilities. The fee structure is designed to evolve when the product secures a Category III CPT code and subsequently a Category I CPT code, aligning the reimbursement rates with established market guidance. This development builds on previous partnerships that have already introduced EchoSolv AS to 36 affiliated hospitals and cardiology practices, underlining the technology’s potential to enhance detection rates for severe aortic stenosis. The initiative is bolstered by comprehensive training programs underway for SARC MedIQ’s sales force, which are soon to extend into the provider network. Management views the collaboration as instrumental in reducing Echo IQ’s sales and distribution costs while accelerating market penetration in the United States. Executives from both companies have expressed confidence that the integration will not only drive new business opportunities but also offer a reliable revenue stream in the coming quarters, reflecting the growing trend of AI-driven diagnostic tools in healthcare. Analysts observing the announcement might view the news with a bullish outlook. The partnership is expected to fast-track the commercialization of an innovative diagnostic tool in a large and receptive market, lower cost bases through third-party sales, and potentially offer consistent revenue growth with favorable reimbursement adjustments in the future. On the bearish side, there remain risks associated with regulatory milestones such as achieving the necessary CPT codes, as well as possible integration challenges that could delay revenue realization. For beginner traders, this development signals cautious optimism as the company leverages a seasoned US partner to drive its expansion in a competitive yet opportunity-rich market.